

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM F-1**  
**REGISTRATION STATEMENT**  
*UNDER*  
*THE SECURITIES ACT OF 1933*

---

**Autolus Therapeutics plc**

(Exact name of registrant as specified in its charter)

---

**England and Wales**  
(State or other jurisdiction of  
incorporation or organization)

**2836**  
(Primary Standard Industrial  
Classification Code Number)

**Not applicable**  
(I.R.S. Employer  
Identification No.)

**Forest House  
58 Wood Lane  
White City  
London W12 7RZ  
United Kingdom  
Tel: +44 20 3829 6230**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

---

**Corporation Service Company  
1180 Avenue of the Americas, Suite 210  
New York, NY 10036  
+1 800 927 9801**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

---

**Darren K. DeStefano  
Christian E. Plaza  
Brian F. Leaf  
Courtney T. Thorne  
Cooley LLP  
11951 Freedom Drive  
Reston, VA 20190-5656  
+1 703 456 8000**

**Copies to:  
Ed Lukins  
Edward Dyson  
Cooley (UK) LLP  
Dashwood  
69 Old Broad Street  
London EC2M 1QS  
United Kingdom  
+44 20 7785 9355**

**Patrick O'Brien  
Emily Oldshue  
Ropes & Gray LLP  
Prudential Tower  
800 Boylston Street  
Boston, MA 02199  
+1 617 951 7000**

**Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective.**

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (File No. 333-230767)

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

CALCULATION OF REGISTRATION FEE

TITLE OF EACH CLASS OF SECURITIES BEING REGISTERED	AMOUNT TO BE REGISTERED(2)	PROPOSED MAXIMUM OFFERING PRICE PER SHARE(3)(4)	PROPOSED MAXIMUM AGGREGATE OFFERING PRICE(4)	AMOUNT OF REGISTRATION FEE(4)
Ordinary shares, nominal value \$0.000042 per share(1)	230,000	\$24.00	\$5,520,000	\$669.02

- (1) These ordinary shares are represented by American Depositary Shares (“ADSs”), each of which represents one ordinary share of the registrant. ADSs issuable upon deposit of the ordinary shares registered hereby have been registered pursuant to a separate registration statement on Form F-6 (File No. 333-224837), including any amendments thereto.
- (2) The registrant previously registered securities at an aggregate offering price not to exceed \$140,553,000 on a Registration Statement on Form F-1, as amended (File No. 333-230767), which was declared effective on April 10, 2019 (the “Initial Registration Statement”). Represents only the number of ordinary shares being registered pursuant to this Registration Statement, which includes 30,000 ordinary shares represented by ADSs that the underwriters have the option to purchase, and are in addition to the 4,600,000 ordinary shares represented by ADSs that were registered pursuant to the Initial Registration Statement, which included 600,000 ordinary shares represented by ADSs that the underwriters have the option to purchase.
- (3) Based on the public offering price of \$24.00 per ADS.
- (4) The registration fee is calculated in accordance with Rule 457(a) under the Securities Act of 1933, as amended, based on the proposed maximum aggregate offering price. The registrant previously registered securities at an aggregate offering price not to exceed \$140,553,000 on a Registration Statement on Form F-1, as amended (File No. 333-230767), which was declared effective by the Securities and Exchange Commission on April 10, 2019. In accordance with Rule 462(b) under the Securities Act, an additional amount of securities having a proposed maximum aggregate offering price of no more than 20% of the maximum aggregate offering price of the securities eligible to be sold under the Initial Registration Statement is hereby registered, which includes ordinary shares represented by ADSs issuable upon exercise of the underwriters’ option to purchase additional ADSs and does not include the securities that the registrant previously registered on the Initial Registration Statement.

The registration statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.

---

**EXPLANATORY NOTE AND  
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE**

This Registration Statement (the “Registration Statement”) is being filed with the U.S. Securities and Exchange Commission (the “Commission”) with respect to the registration of additional ordinary shares, nominal value \$0.000042 per share, of Autolus Therapeutics plc (the “Registrant”), pursuant to Rule 462(b) and General Instruction V of Form F-1, both promulgated under the Securities Act of 1933, as amended (the “Securities Act”). This Registration Statement incorporates by reference the contents of, including all amendments and exhibits thereto, the Registration Statement on Form F-1, as amended (File No. 333-230767) (the “Initial Registration Statement”), which the Commission declared effective on April 10, 2019, and is being filed solely for the purpose of increasing the number of ordinary shares represented by American Depositary Shares (“ADSs”) to be offered in the public offering by 230,000 shares, including 30,000 shares represented by ADSs that may be sold pursuant to the underwriters’ option to purchase additional ADSs. The additional shares that are being registered for sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in the Calculation of Registration Fee table contained in the Initial Registration Statement. The required opinion and consents are listed on an Exhibit Index attached hereto and incorporated by reference into this Registration Statement.

## EXHIBIT INDEX

<b>Exhibit Number</b>	<b>Description</b>
5.1	<a href="#"><u>Opinion of Cooley_(UK)_LLP (incorporated by reference to Exhibit 5.1 to the Registration Statement on Form F-1, as amended (File No. 333-230767), filed with the Commission on April 8, 2019).</u></a>
23.1	<a href="#"><u>Consent of Ernst &amp; Young LLP, registered public accounting firm.</u></a>
23.3	<a href="#"><u>Consent of Cooley_(UK)_LLP (included in Exhibit 5.1).</u></a>
24.1	<a href="#"><u>Power of Attorney (included on the signature page of the Registration Statement on Form F-1 (File No. 333-230767), filed with the Commission on April 8, 2019 and incorporated herein by reference).</u></a>

## SIGNATURES

Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of London, United Kingdom, on April 10, 2019.

### AUTOLUS THERAPEUTICS PLC

By: /s/ Christian Itin  
Christian Itin  
Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

Name	Title	Date
<u>/s/ Christian Itin</u> Christian Itin, Ph.D.	Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer)	April 10, 2019
<u>/s/ Andrew Oakley</u> Andrew Oakley	Senior Vice President, Chief Financial Officer (Principal Financial Officer)	April 10, 2019
<u>/s/ Dominic Moreland</u> Dominic Moreland	Vice President, Finance (Principal Accounting Officer)	April 10, 2019
<u>*</u> Joseph Anderson, Ph.D.	Director	April 10, 2019
<u>*</u> Linda Bain	Director	April 10, 2019
<u>*</u> John Berriman	Director	April 10, 2019
<u>*</u> Cynthia Butitta	Director	April 10, 2019
<u>*</u> Kapil Dhingra, M.D.	Director	April 10, 2019
<u>*</u> Martin Murphy, Ph.D.	Director	April 10, 2019

\*By: /s/ Christian Itin  
Christian Itin  
Attorney-in-fact

---

**SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF THE REGISTRANT**

Pursuant to the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of Autolus Therapeutics plc, has signed this registration statement or amendment thereto on April 10, 2019.

**AUTOLUS INC.**

By: /s/ Matthias Alder

Name: Matthias Alder

Title: Senior Vice President, Chief Business Officer and  
Corporate Secretary

## Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement on Form F-1 filed pursuant to Rule 462(b) of the Securities Act of 1933 of the reference to our firm under the caption “Experts” and to the incorporation by reference of our reports dated November 21, 2018 and February 25, 2019, with respect to the consolidated financial statements of Autolus Therapeutics plc included in its Annual Report (Form 20-F) for the year ended September 30, 2018 and Transition Report (Form 20-F) for the three months ended December 31, 2018, incorporated by reference in the Registration Statement (Form F-1 No. 333-230767) and related Prospectus of Autolus Therapeutics plc for the registration of its American Depositary Shares.

/s/ Ernst & Young LLP

Reading, United Kingdom

April 10, 2019